From BZ’s EVCon Event: Helbiz CFO Giulio Profumo Begins Speaking

https://www.youtube.com/watch?v=IOEwtEb2M0M

byBill Haddad

September 22, 2021

1 minute read

Inozyme Pharma Announces $73M Underwritten Offering Priced At-the-Market

By Benzinga Newsdesk

April 14, 8:17 AM

Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten

INZY

Stifel Initiates Coverage On Inspirato with Hold Rating, Announces Price Target of $10

By Benzinga Newsdesk

March 17, 6:18 AM

Stifel analyst Scott Devitt initiates coverage on Inspirato (NASDAQ:ISPO) with a Hold rating and announces Price Target of $10.

ISPO

News

President Biden to Sign Executive Order Seeking New Prescription Drug Cost Savings

By Charles Gross

October 14, 5:07 AM

-Reuters Citing Official https://www.reuters.com/world/us/biden-sign-order-seeking-new-prescription-drug-cost-savings-official-2022-10-14/

AZN

Canaccord Genuity Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $32

By Benzinga Newsdesk

July 20, 6:20 AM

Canaccord Genuity analyst John Newman initiates coverage on Arcellx (NASDAQ:ACLX) with a Buy rating and announces Price Target of $32.

ACLX

From BZ’s EVCon Event: Helbiz CFO Giulio Profumo Begins Speaking

Related Posts

Inozyme Pharma Announces $73M Underwritten Offering Priced At-the-Market

Stifel Initiates Coverage On Inspirato with Hold Rating, Announces Price Target of $10

President Biden to Sign Executive Order Seeking New Prescription Drug Cost Savings

Canaccord Genuity Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $32